Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Subscriptions
  • Contact
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Subscriptions
  • Contact

COVID-19 updates

Picture

COVID-19 Update #111 for 11/24/2021

11/24/2021

0 Comments

 
COVID-19 Vaccines
 
The FDA approved a booster dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines for all patients 18 and older on 11/18/2021. On 11/19/2021, the CDC recommended booster doses of both vaccines for the same group of patients. All patients have already been approved to receive a booster of the J&J vaccine.
 
Pfizer and BioNTech announced that follow-up data from their COVID-19 vaccine teen study (NCT04368728) demonstrated 100% efficacy from seven days after the second dose through four months.

0 Comments

COVID-19 Update #110 for 11/19/2021

11/19/2021

0 Comments

 
COVID-19 Vaccines
 
A Norwegian case–control study examined first-trimester pregnancies in 13,956 women from registry data and found no evidence of an increased risk for early pregnancy loss after Covid-19 vaccination.
 
COVID-19 Anti-inflammatories
 
In the 28-day, 2,052 patient, Phase III, PREPARE-IT 2 trial (NCT04460651), treatment with icosapent ethyl did not reduce hospitalization or death compared to placebo (13.69% vs 11.16%) in nonhospitalized Argentinian COVID-19 patients.
 
COVID-19 Antibodies
 
AZ announced that after six months 4,991 patients enrolled in the PROVENT trial, no cases of severe COVID-19 or COVID-19-related death occurred in patients that received AZD7442 compared to five cases of severe COVID-19 and two COVID-related deaths with placebo.
 
In the 15-day, 511 patient, Phase III, C3PO trial (NCT04355767 treatment with convalescent plasma did not reduce emergency treatment, hospitalization or death in high-risk outpatients with COVID-19.
 
In the 29-day, 583 patient, Phase III, COMET-ICE trial (NCT04545060), 1% of patients treated with sotrovimab
were hospitalized or died compared to placebo in outpatients with COVID-19 who were at high risk of progression to severe disease. 

0 Comments

COVID-19 Update #109 for 11/10/2021

11/10/2021

0 Comments

 
​COVID-19 Vaccines
 
In a final analysis of the 30,451 patient, Phase III COVE trial (NCT04470427), vaccine efficacy was 93.2% to prevent COVID-19 and 98.2% to prevent severe disease with the Moderna COVID-19 vaccine.
 
In a 2,268 patient, Phase II/III trial (NCT04816643), two 10 mcg doses of the Pfizer-BioNTech COVID-19 vaccine given 21 days apart, to children 5 to 11 years, produced antibody titers comparable to the levels seen with two 30 mcg adult doses in adolescents and young adults age 16 to 25 years. Vaccine effectiveness was 90.7% one month after the second injection.
 
COVID-19 Antivirals
 
Pfizer announced interim data from 1,219 patients enrolled in the 28-day, 3,000 patient, Phase III, EPIC-HR trial (NCT04960202), where 0.8% of patients treated with the combination of PF-07321332 and ritonavir were hospitalized or died compared to 7% with placebo in unvaccinated patients with mild-to-moderate COVID-19 at risk to progress to severe illness. Due to the 89% reduction in COVID-19-related hospitalization or death, the FDA agreed with Data Monitoring Committee, the trial could be stopped. Pfizer plans to submit the data as part of a rolling NDA.
 
The United Kingdom Medicines and Healthcare products Regulatory Agency approved molnupiravir for the treatment of mild-to-moderate COVID-19 in adults at risk to develop severe illness.
 
COVID-19 Anti-inflammatories
 
In the seven-day, 203 patient, Phase II, CONTAIN trial (NCT04435795), treatment with inhaled and intranasal ciclesonide did not improve symptom resolution compared to placebo in low-risk, Canadian outpatients with COVID-19.
 
COVID-19 Antibodies
 
In a long term extension of the Phase III, PREVENTION trial, patients that received REGEN-COV had an 81.6% reduction in developing symptomatic COVID-19 compared to placebo after eight months.
0 Comments

COVID-19 Update #108 for 11/3/2021

11/3/2021

0 Comments

 
COVID-19 Vaccines
 
Pfizer and BioNTech COVID-19 vaccine approved for use in children 5 to 11 years of age.
  • Pfizer and BioNTech announced that in a 2,268 patient, Phase II/III trial (NCT04816643), two 10 mcg doses of their COVID-19 vaccine given 21 days apart, to children 5 to 11 years, produced antibody titers comparable to the levels seen with two 30 mcg adult doses in adolescents and young adults age 16 to 25 years. 
  • An FDA review of data for the Pfizer-BioNTech COVID-19 vaccine in children ages 5 to 11 years, found benefits to outweigh the risks for this age group. Adverse events were similar to adolescents and young adults ages 16 to 25 years. Based on limited follow-up, vaccine effectiveness was estimated to be 90.7% with no cases of severe COVID-19. 
  • The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17-0 with one member abstaining to recommend the Pfizer-BioNTech COVID-19 vaccine in children 5 to 11 years of age.
  • The FDA agreed with VRBPAC and expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include children 5 to 11 years of age. The pediatric dose is two 10 mcg doses given 21-days apart. 
  • While children seem to be less affected by COVID-19 than adults, there has been 8,300 hospitalizations for COVID-19 in children ages 5 to 11 and 146 children have died. In the same age group, 2,316 children have developed multisystem inflammatory syndrome in children (MIS-C) from COVID-19 and nine have died. The mortality rate with COVID-19 in pediatric patients is much higher than influenza. The CDC noted a five-fold increase in pediatric COVID-19 cases attributed the Delta variant this summer.
  • The CDC’s ACIP voted 14 to 0 to recommend use of Pfizer-BioNTech COVID-19 vaccine in children 5 to 11 years of age.
  • The CDC agreed with ACIP and endorsed use of the Pfizer and BioNTech COVID-19 vaccine in children 5 to 11 years of age. ​
Moderna announced the FDA is delaying a decision on use its COVID-19 vaccine in adolescents, 12 to 17 years of age, to allow more time to examine international data on the occurrence of myocarditis. The adolescent dose is the same as the adult dose, two doses of 100 mcg given 28-days apart.
 
Researchers analyzed historical and current data from Olmsted County, Minnesota and found the incidence of cerebral venous sinus thrombosis (CVST) had increased in females who received the J&J COVID-19 vaccine. The highest incidence of CVST was in women 40-49, followed by women aged 30 to 39 years.
 
CDC analysts compared the outcomes of 20,101 fully vaccinated immunocompromised adults to 69,116 fully vaccinated immunocompetent adults and found vaccine effectiveness to prevent COVID-19 related hospitalizations to be 77% for immunocompromised adults compared to 90% for immunocompetent adults. This decrease in effectiveness was present regardless of the type of vaccine used, patient’s geographic location, prevalence of the Delta variant or underlying cause for the immunocompromised state.

0 Comments
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.